<DOC>
	<DOCNO>NCT02961673</DOCNO>
	<brief_summary>A Phase I/Ⅱ Clinical Trial Compare Safety Efficacy HU-014 versus Botox® Subject Moderate Severe Glabellar Lines</brief_summary>
	<brief_title>The Safety Efficacy Study HU-014 Versus Botox® Subject With Moderate Severe Glabellar Lines</brief_title>
	<detailed_description />
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Facial Wrinkle Scale ( FWS ) score &gt; 2 Subject knit brow extremely Volunteer history disease follow . ( myasthenia gravis , EatonLambert syndrome , amyotrophic lateral sclerosis etc . ) From screen , Subject get plastic Surgery include fascioplasty , Prosthesis implantation within 6 Weeks Subject skin disorder include infection scar injection site Subject take medication include skeletal muscle relaxant , Aminoglycoside , lincomycin , anticholinergic drug , benzodiazepine , benzamide etc . Subject take medication include anticoagulant , antithrombotic drug except low dose aspirin ( 325 mg/day ) Any condition , view investigator , would interfere study participation</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>